Huaqing Zhimei
A high-tech biotechnology firm specializing in the industrialization of Bio-3D printing and human-engineered extracellular matrix (hEECM) materials for regenerative medicine and medical aesthetics.
- CEO / Founder
- Liu Boxun
- Team Size
- 51-100
- Stage
- Post-Series A commercialization; operating a 2,000sqm GMP-standard production facility in Shenzhen with established product lines in the medical aesthetics market.
- Total Funding
- $6.2M
- Latest Round
- Series A
- Key Investors
- ["Leaguer Capital (力合创投)","Shaanxi Financial Holding (陕西金控)","Zijing Hongxin (紫荆泓鑫)"]
Technology & Products
Key Products
["h-EECM (Human Engineered Extracellular Matrix) Raw Materials","Meibiyuan (美泌源) Brand - High-end medical aesthetics line","Qingfu Mima (清肤泌码) - Skin repair and regeneration product","Shiguang Mima (时光泌码) - Anti-aging and tissue filling solution","Automated Bio-3D Printing Systems (proprietary R&D equipment)"]
Technological Advantage
Pioneered the transition from 'printing organs' (long-term research) to 'printing factories' (immediate commercialization), solving the scalability and cost issues of high-purity human-derived bioactive materials.
Market & Competition
Target Customers
Medical aesthetics clinics, dermatology hospitals, plastic surgery centers, and pharmaceutical research institutions.
Industry Verticals
["Medical Aesthetics","Regenerative Medicine","Tissue Engineering","Biotechnology"]
Competitors
["Giant Biogene (巨子生物)","Bloomage Biotech (华熙生物)","Trautec (创健医疗)","Regenovo (捷诺飞)"]